EICHORPublic-registry site landscape for NCT07684144, “Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)”, a Obesity study sponsored by Amgen. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07684144 (registry record) |
| Study title | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) |
| Official title | A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus |
| Sponsor | Amgen |
| Condition(s) | Obesity; Overweight; Diabetes Mellitus, Type 2 |
| Phase | PHASE3 |
| Listed sites | 0 |
Patient-friendly overview of this study: eichor.com/study/NCT07684144.
Eichor generates a preliminary site-risk snapshot for NCT07684144 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Obesity trials
← Eichor home · All tracked trials · Obesity studies · Weekly briefs
